Research conducted in animals and in in vitro cell cultures indicates that aminoindanes are relatively benign at recreational doses; however, the effects on humans have not yet been reported.[1] MDAI and 5-IAI are reported to be highly potent selective serotonin releasing agents. Animal studies have shown that these analogues did not present any long-term neurotoxicity at the levels administered,[2] but slight neurotoxicity on rodents was shown after administration of very high doses of 5-IAI.[3]



[1] Sainsbury, P.D., Kicman, A.T., et al., ‘Aminoindanes - the next wave of ‘legal highs’?’, Drug Testing and Analysis, 2011, 3, 479-82

[2] Johnson, M.P., Frescas, S.P., et al., ‘Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy) methamphetamine (MDMA)’, Journal of Medicinal Chemistry, 1991, 34, 1662; Monte A.P., Maronalewicka, D., et al., ‘Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogs of 3,4-(methylenedioxy)amphetamine’, Journal of Medicinal Chemistry, 1993, 36, 3700; Marona-Lewicka, D., Rhee, G.S., et al., ‘Reinforcing effects of certain serotonin-releasing amphetamine derivatives’, Pharmacology Biochemistry and Behavior, 1996, 53, 99-105

[3] Nichols, D., Johnson, M. P. and Oberlender, R., ‘5-iodo-2-aminoindan, a nonneurotoxic analog of para-iodoamphetamine’, Pharmacology Biochemistry & Behavior, 1991, 38, 135-39

For more information, please see